Maternal Longevity Indicator and Your Genetics
Maternal Longevity Genetics: APOE, LPA, and CHRNA3 | ExomeDNA
By the ExomeDNA Research Team | Last reviewed May 2026
Research base: Moderate.
What is maternal longevity as a genetic trait?
Maternal longevity genetics uses mother's age at death or attained age as a proxy phenotype for studying heritable influences on female lifespan. Because individual longevity unfolds over an entire lifetime, using parental ages enables genome-wide association studies to identify genetic signals with population-scale statistical power—a person whose mother lived to older ages may carry genetic variants that supported that longevity, with potential relevance to the offspring's own genetic background.
Favorable genetic scores in this analysis are associated with longer-lived mothers in the study population. The maternal longevity gene set is strikingly different from the paternal longevity gene set, reflecting distinct biological factors in female aging: APOE dominates the maternal signal, alongside genes linked to lipoprotein(a) levels, fibrinolysis, and nicotinic receptor biology tied to smoking behavior.
The genetics behind maternal longevity
The strongest genetic signals for maternal longevity include variants near APOE, LPA, PLG, RNF123, CHRNA3, and CHRNB4. This gene set reflects three distinct biological pathways: APOE-mediated lipoprotein handling and neurodegenerative risk, lipoprotein(a)/fibrinolysis biology, and nicotinic acetylcholine receptor variation linked to smoking behavior.
APOE is the dominant maternal longevity signal, with an l2g score of 0.957—much higher than its contribution to paternal longevity. APOE encodes apolipoprotein E, which mediates clearance of lipoprotein remnant particles and lipid redistribution in the brain and periphery. The three major APOE isoforms (ε2, ε3, ε4) have profoundly different effects: the ε4 allele is the largest common genetic risk factor for Alzheimer's disease and is associated with elevated cardiovascular susceptibility and shorter lifespan across multiple population studies. The ε2 allele is associated with favorable lipoprotein profiles and longer lifespan. The prominence of APOE in maternal longevity—more than paternal—may reflect the higher absolute rates of Alzheimer's disease in women compared to men, making APOE genotype a larger determinant of female longevity trajectories.
APOE accounts for the largest single-gene effect on Alzheimer's disease risk in the general population, with the ε4 allele associated with substantially shorter lifespan across multiple population cohorts. Its dominance in maternal longevity genetics reflects the higher female burden of Alzheimer's disease in late life (Wright et al., 2019).
LPA encodes apolipoprotein(a), the protein backbone of lipoprotein(a) [Lp(a)], an independent cardiovascular risk particle. LPA variants are the primary genetic determinants of Lp(a) blood levels, which vary more than tenfold across individuals largely due to LPA genetics. High Lp(a) is associated with elevated cardiovascular and cerebrovascular susceptibility; favorable LPA variants that lower Lp(a) are associated with longer survival. PLG encodes plasminogen, the zymogen precursor to plasmin, the principal fibrinolytic enzyme that breaks down blood clots. PLG is physically adjacent to LPA on chromosome 6q26-27. Reduced fibrinolytic capacity may increase thromboembolic susceptibility, contributing to the PLG signal in maternal longevity.
CHRNA3 and CHRNB4 encode nicotinic acetylcholine receptor subunits alpha-3 and beta-4, respectively. These genes reside in the chromosome 15q25 locus, which contains the strongest common genetic signals for smoking quantity—cigarettes smoked per day, nicotine dependence, and smoking-related lung cancer. Individuals with certain CHRNA3/CHRNB4 variants are genetically predisposed to smoke more heavily if they smoke, and to experience greater difficulty quitting. Their appearance in maternal longevity genetics implies that genetically mediated smoking behavior is among the heritable components shaping how long mothers live—consistent with smoking being one of the largest modifiable determinants of female lifespan in the study generation.
What the research says
Wright et al. (2019) analyzed paternal and maternal longevity separately in a prospective cohort design, revealing the divergent genetic architectures between the two. While paternal longevity is dominated by cardiovascular lipid metabolism genes (SORT1, LDLR, LPL), maternal longevity is governed by APOE, Lp(a), and smoking behavior genetics. This sex-differential pattern aligns with epidemiological mortality data: women survive longer on average, their late-life mortality is disproportionately shaped by Alzheimer's disease and stroke, and smoking is among the leading causes of premature female mortality in the twentieth century cohorts that inform these genetic studies.
The biological interpretation of maternal longevity genetics is that female lifespan is heritably influenced by neurodegenerative and cerebrovascular pathways (APOE), clotting and fibrinolytic capacity (LPA, PLG), and genetically mediated smoking behavior (CHRNA3, CHRNB4). Each of these pathways represents a biologically distinct mechanism connecting genetics to longevity outcomes.
Maternal longevity is genetically distinct from paternal longevity: APOE dominates the maternal signal (versus lipid transport genes in paternal), with LPA and CHRNA3 reflecting Lp(a)-driven cardiovascular risk and smoking-mediated lifespan effects specific to the maternal genetic architecture (Wright et al., 2019).
How maternal longevity genetics affects you
The genetic variants in maternal longevity analysis are associated with biological pathways that collectively shape susceptibility across the brain, cardiovascular system, and behavior. APOE genotype influences both cardiovascular lipid handling and neural lipid transport in ways that affect long-term brain health trajectories. LPA variants shape Lp(a) levels, a cardiovascular risk factor that until recently had limited therapeutic options but now has specific interventions in development and available. CHRNA3/CHRNB4 variants affect the neurobiology of nicotine response—informative context for understanding individual variation in smoking behavior and its health consequences.
Working with your profile
The maternal longevity gene set points to three actionable domains. For the APOE pathway: maintaining cardiovascular and metabolic health through diet, exercise, and blood pressure management protects against both cardiovascular and neurodegenerative disease trajectories. The Mediterranean diet pattern in particular has shown consistent associations with favorable outcomes across both cardiovascular and brain health endpoints. For the Lp(a)/fibrinolysis pathway: Lp(a) measurement is increasingly available through clinical testing, and emerging therapies specifically targeting Lp(a) are in clinical development.
For the smoking pathway: CHRNA3/CHRNB4 variants that increase nicotine dependence make smoking cessation biologically harder for some individuals, but the absolute health benefit of quitting remains substantial regardless of genetic background. Smoking is one of the most powerful modifiable determinants of lifespan, and cessation support strategies that account for nicotine dependence genetics—including combination pharmacotherapy—are available.
This content is provided for educational purposes only.
Related traits and genes
Maternal longevity genetics overlaps with Alzheimer's disease risk (APOE), cardiovascular disease risk (APOE, LPA), and smoking behavior traits (CHRNA3, CHRNB4). LPA variants also appear in coronary artery disease and stroke genetics. PLG is more specific to fibrinolytic capacity and thromboembolic traits. The APOE gene is one of the most pleiotropic in human genetics, appearing across cardiovascular, neurological, and aging phenotypes. Paternal longevity shares APOE but diverges sharply in its other top signals, underscoring the sex-differential nature of the heritable longevity landscape.